Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Impacted by COVID-19, Industry Research up to 2030

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market reached US$ 3.57 Bn in 2019 (up by 4.7% over 2018). Outbreak of Covid-19 in the short-term, backed by “innovation” in the long run, is expected to drive the market.

Sepsis, toxic shock syndrome, bacteremia, osteomyelitis, endocarditis, meningitis, pneumonia are amongst the life-threatening diseases caused by Staphylococcus Aureus bacteria. These diseases are cured by antibiotics.

Some form of staphylococcus aureus that has developed resistance to a broad range of antibiotics fall in the category of “Methicillin-Resistant Staphylococcus Aureus (MRSA)”. This resistance is one of the key factors driving the market in the near future as well as extensive research ought to be on the anvil to devise new medications.

According to FMI’s latest study, the rising incidences of MRSA all over the world are likely to create demand for safe and efficient drugs during the forecast period.

“Antibiotics manufacturers are facing a grim situation, owing to weak investor confidence in this category. However, government, and non-profit grants are likely to sustain the R&D momentum, and offset some of the sluggishness during the forecast period,” opines an FMI analyst.

Request For Sample Report @

Covid-19 Pandemic: A Short-term Upholsterer

Outbreak of novel corona virus has resulted in short-term considerable increase in the number of MRSA infections. This number is expected to boost the market demand for MRSA antibiotics during the ongoing Covid-19 crisis. As per the latest data, around 2.5 million people have been infected by Covid-19 so far.

Key Takeaways of MRSA Treatment Market Study 

  • In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.
  • By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
  • By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
  • Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
  • North America is the highest revenue generating market by region due to high incidence of MRSA infections
  • Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2018, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.

Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treated  

As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.

About MRSA Treatment Market Study

MRSA treatment market, a new study from Future Market Insights, opines on the MRSA treatment from 2015 – 2019 and presents demand projections between 2020 and 2030 on the basis of drug class (glycopeptides, lipopeptide, oxazolidinones, glycylcycline, streptogramins, lincomycin, tetracycline, lipoglycopeptides, antiseptics, naturals/herbals, and others), indication (skin and soft tissue infections (SSTIs), pneumonia, bloodstream infections, surgical and medical infections, and others), route of administration (intravenous, oral, topical, nasal, cutaneous, and intramuscular), types of MRSA (healthcare acquired MRSA, community acquired MRSA, and hospital acquired MRSA), and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies) across seven prominent regions.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. COVID19 Crisis Analysis

        4.1.1. Current COVID19 Statistics and Probable Future Impact

        4.1.2. Current GDP Projection and Probable Impact

        4.1.3. Current Economic Projection as compared to 2008 Economic analysis

        4.1.4. COVID19 and Impact Analysis

   Revenue By Drug Class

   Revenue By Route of Administration

   Revenue By Country

        4.1.5. 2020 Market Scenario

        4.1.6. Quarter by Quarter Forecast

        4.1.7. Projected recovery Quarter

        4.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact

    4.2. Macro-Economic Factors

        4.2.1. Global GDP Growth Outlook

        4.2.2. Global Healthcare Outlook

    4.3. Forecast Factors – Relevance & Impact

        4.3.1. Historical Growth of Top Players

        4.3.2. New Product Approval and Launch

        4.3.3. Adoption of MRSA Treatment

        4.3.4. Cost of MRSA Treatment

        4.3.5. Increasing Epidemic of MRSA Infections

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints

        4.4.3. Opportunities

5. Market Context

    5.1. Product USPs/ Features

    5.2. Epidemiological Forecast for MRSA (2014–2024)

        5.2.1.  Hospitalized Incident Cases of MRSA

        5.2.2.  Sex-Specific Hospitalized Incident Cases of MRSA

        5.2.3.  Age-Specific Hospitalized Incidence of MRSA

        5.2.4. Age-Standardized Hospitalized Incidence Rate of MRSA

    5.3. Pipeline Assessment

        5.3.1. Pipeline Overview

        5.3.2. Pipeline Breakdown by Region/Country

        5.3.3. Pipeline Breakdown by Molecule Type and Target

        5.3.4. Drug Review Designations

        5.3.5. Products in Clinical Development

    5.4. New Product Approvals

    5.5. Clinical Trial Assessment

        5.5.1. Clinical Trials Overview

        5.5.2. Top Sponsors of Clinical Trials in MRSA

        5.5.3. Trial Breakdown by Region

        5.5.4. Therapy Area Perspective

        5.5.5. Enrolment Analytics

    5.6. Product Adoption / Route of Administration Analysis

    5.7. Regulatory Scenario

Leave a comment

Your email address will not be published.